Eric Van Cutsem
Universitair Ziekenhuis Leuven
2 papers in the Anchorcite directory, published between 2004 and 2013, cited 11,922 times in total.
ORCID profileResearch topics
- Cancer Treatment and Pharmacology · 1 paper
- Pancreatic and Hepatic Oncology Research · 1 paper
- Pancreatitis Pathology and Treatment · 1 paper
- Colorectal Cancer Treatments and Studies · 1 paper
- HER2/EGFR in Cancer Research · 1 paper
- Colorectal Cancer Surgical Treatments · 1 paper
Frequent co-authors
- Daniel D. Von Hoff · 1 paper
- Thomas J. Ervin · 1 paper
- Francis P. Arena · 1 paper
- Elena Gabriela Chiorean · 1 paper
- Jeffrey R. Infante · 1 paper
- Malcolm J. Moore · 1 paper
- Thomas E. Seay · 1 paper
- Sergei Tjulandin · 1 paper
Papers
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine · 2013 · 6,853 citations
BACKGROUND: In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted a phase 3 study of the efficacy and safety of the combination versus gemcitabine monotherapy…
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine · 2004 · 5,069 citations
BACKGROUND: The epidermal growth factor receptor (EGFR), which participates in signaling pathways that are deregulated in cancer cells, commonly appears on colorectal-cancer cells. Cetuximab is a monoclonal antibody that specifically blocks the EGFR. We compared the efficacy of cetuximab in…
Metadata from OpenAlex (CC0).